Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma
Andrea Rinaldi, Ivo Kwee, Monica Taborelli, et al.
British Journal of Haematology (2005) Vol. 132, Iss. 3, pp. 303-316
Closed Access | Times Cited: 194

Showing 51-75 of 194 citing articles:

Inhibiting B-Cell Receptor Signaling Pathways in Chronic Lymphocytic Leukemia
Jan A. Burger
Current Hematologic Malignancy Reports (2011) Vol. 7, Iss. 1, pp. 26-33
Closed Access | Times Cited: 53
Transcription and translation are primary targets of Pim kinase inhibitor SGI-1776 in mantle cell lymphoma
Qingshan Yang, Lisa S. Chen, Sattva S. Neelapu, et al.
Blood (2012) Vol. 120, Iss. 17, pp. 3491-3500
Open Access | Times Cited: 53
The Syk kinase as a therapeutic target in leukemia and lymphoma
Dimitar G. Efremov, Luca Laurenti
Expert Opinion on Investigational Drugs (2011) Vol. 20, Iss. 5, pp. 623-636
Closed Access | Times Cited: 52
Inhibitors of BCR signalling interrupt the survival signal mediated by the micro‐environment in mantle cell lymphoma
Sophie Bernard, Damien Danglade, Laura Gardano, et al.
International Journal of Cancer (2014) Vol. 136, Iss. 12, pp. 2761-2774
Open Access | Times Cited: 50
The Selective Syk Inhibitor P505-15 (PRT062607) Inhibits B Cell Signaling and Function In Vitro and In Vivo and Augments the Activity of Fludarabine in Chronic Lymphocytic Leukemia
Stephen E. Spurgeon, Greg Coffey, Luke B. Fletcher, et al.
Journal of Pharmacology and Experimental Therapeutics (2012) Vol. 344, Iss. 2, pp. 378-387
Open Access | Times Cited: 50
SYK regulates mTOR signaling in AML
Julia Carnevale, Linda Ross, Alexandre Puissant, et al.
Leukemia (2013) Vol. 27, Iss. 11, pp. 2118-2128
Open Access | Times Cited: 48
NF-κB Activation in Lymphoid Malignancies: Genetics, Signaling, and Targeted Therapy
Paula Grondona, Philip Bucher, Klaus Schulze‐Osthoff, et al.
Biomedicines (2018) Vol. 6, Iss. 2, pp. 38-38
Open Access | Times Cited: 46
The molecular pathogenesis of mantle cell lymphoma
Niklas Vogt, Beiying Dai, Tabea Erdmann, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2016) Vol. 58, Iss. 7, pp. 1530-1537
Closed Access | Times Cited: 45
T-Cell Levels Are Prognostic in Mantle Cell Lymphoma
Lina Nygren, Agata M. Wasik, Stefanie Baumgartner-Wennerholm, et al.
Clinical Cancer Research (2014) Vol. 20, Iss. 23, pp. 6096-6104
Open Access | Times Cited: 43
IRAK-4 inhibition: emavusertib for the treatment of lymphoid and myeloid malignancies
Ricardo Parrondo, Madiha Iqbal, Reinhard von Roemeling, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 11
Comparative genome‐wide profiling of post‐transplant lymphoproliferative disorders and diffuse large B‐cell lymphomas
Andrea Rinaldi, Ivo Kwee, Giulia Poretti, et al.
British Journal of Haematology (2006) Vol. 134, Iss. 1, pp. 27-36
Closed Access | Times Cited: 58
New molecular targets in mantle cell lymphoma
Samir Parekh, Marc A. Weniger, Adrian Wiestner
Seminars in Cancer Biology (2011) Vol. 21, Iss. 5, pp. 335-346
Open Access | Times Cited: 43
Ibrutinib for the Treatment of Mantle Cell Lymphoma
Alex F. Herrera, Eric D. Jacobsen
Clinical Cancer Research (2014) Vol. 20, Iss. 21, pp. 5365-5371
Closed Access | Times Cited: 41
New roles for B cell receptor associated kinases: when the B cell is not the target
Phuong‐Hien Nguyen, Emanuel Niesen, Michael Hallek
Leukemia (2019) Vol. 33, Iss. 3, pp. 576-587
Closed Access | Times Cited: 33
Review and prospects of targeted therapies for Spleen tyrosine kinase (SYK)
Zhaozhao Wang, S. Qu, Jiahao Yuan, et al.
Bioorganic & Medicinal Chemistry (2023) Vol. 96, pp. 117514-117514
Closed Access | Times Cited: 9
Phosphorylation of the activation loop tyrosines is required for sustained Syk signaling and growth factor-independent B-cell proliferation
Laura Carsetti, Luca Laurenti, Stefania Gobessi, et al.
Cellular Signalling (2009) Vol. 21, Iss. 7, pp. 1187-1194
Closed Access | Times Cited: 45
Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers
Birgitta Sander
Seminars in Diagnostic Pathology (2011) Vol. 28, Iss. 3, pp. 245-255
Closed Access | Times Cited: 35
Mantle cell lymphoma: state of the art.
Alan P Skarbnik, André Goy
PubMed (2015) Vol. 13, Iss. 1, pp. 44-55
Closed Access | Times Cited: 33
Ibrutinib in mantle cell lymphoma patients: glass half full? Evidence and opinion
Deborah M. Stephens, Stephen E. Spurgeon
Therapeutic Advances in Hematology (2015) Vol. 6, Iss. 5, pp. 242-252
Open Access | Times Cited: 29
B-cell receptor signaling in chronic lymphocytic leukemia and other B-cell malignancies.
Stefan Koehrer, Jan A. Burger
PubMed (2016) Vol. 14, Iss. 1, pp. 55-65
Closed Access | Times Cited: 29
Development of a murine model for blastoid variant mantle-cell lymphoma
R. Ford, Long Shen, Yen Chiu Lin-Lee, et al.
Blood (2007) Vol. 109, Iss. 11, pp. 4899-4906
Open Access | Times Cited: 39
High‐resolution genomic screening in mantle cell lymphoma—specific changes correlate with genomic complexity, the proliferation signature and survival
Anna Margrét Halldórsdóttir, Birgitta Sander, Hanna Göransson, et al.
Genes Chromosomes and Cancer (2010) Vol. 50, Iss. 2, pp. 113-121
Closed Access | Times Cited: 34
Bruton's tyrosine kinase inhibitors in B‐cell non‐Hodgkin's lymphomas
Lapo Alinari, Carl Quinion, KA Blum
Clinical Pharmacology & Therapeutics (2015) Vol. 97, Iss. 5, pp. 469-477
Closed Access | Times Cited: 28
In pursuit of a moving target: nanotherapeutics for the treatment of non-Hodgkin B-cell lymphoma
Christopher Knapp, Kathryn A. Whitehead
Expert Opinion on Drug Delivery (2014) Vol. 11, Iss. 12, pp. 1923-1937
Closed Access | Times Cited: 28
Sorafenib Inhibits Cell Migration and Stroma-Mediated Bortezomib Resistance by Interfering B-cell Receptor Signaling and Protein Translation in Mantle Cell Lymphoma
Sílvia Xargay‐Torrent, Mònica López‐Guerra, Arnau Montraveta, et al.
Clinical Cancer Research (2012) Vol. 19, Iss. 3, pp. 586-597
Open Access | Times Cited: 28

Scroll to top